AUS
NZ
UK
CA
USA
IND
Highlights
Indivior PLC (LON:INDV, NASDAQ:INDV) to cancel its secondary listing on the London Stock Exchange.
Primary listing on Nasdaq to be retained in line with U.S. business concentration.
UK shareholders using Depositary Interests and Corporate Sponsored Nominee accounts will need to transition for Nasdaq trading access.
Indivior PLC (LON:INDV, NASDAQ:INDV), part of the pharmaceuticals sector, has announced a decision to cancel its secondary listing on the London Stock Exchange. This change is scheduled to take effect toward the end of July. Indivior is also listed on the Nasdaq index, where it maintains its primary listing. The company is currently included in the FTSE All-Share Index and has previously been associated with the broader categorisation of ftse 100 companies due to its market profile.
Strategic Shift Toward U.S. Market Operations
The company’s shift in listing strategy aligns with the operational reality that a large portion of its revenue and trading activity originates in the United States. This is driven by its lead product, SUBLOCADE, which is marketed extensively in the U.S. healthcare system. Indivior has indicated that its decision reflects the geographical composition of its shareholder base and trade volume, both of which are predominantly U.S.-centric.
Cost and Compliance Streamlining Through Delisting
The cancellation of the secondary listing is part of a broader effort to streamline financial and regulatory overhead. By concentrating on a single primary exchange, Indivior intends to reduce the administrative requirements and compliance costs associated with dual listings. The delisting process does not require a shareholder vote and has been framed as a structural simplification rather than a change in operational status.
No Impact for Direct Ordinary Shareholders
The company has clarified that this decision will not impact those who directly Ordinary Shares or those with holdings through DTC brokers. These stakeholders will continue to have uninterrupted access to Indivior’s shares through the Nasdaq exchange. Trading and ownership rights remain unaffected for this group of shareholders.
Action Required for Depositary Interest and Nominee Account Holders
UK-based investors using Depositary Interests or Corporate Sponsored Nominee services will be required to convert their holdings to enable trading through Nasdaq. Indivior has communicated that these holders will need to take specific administrative steps to continue access to their shareholding post-delisting. Detailed instructions are expected to be issued through official channels closer to the effective date.
Post-Delisting Regulatory Landscape
Despite the exit from the London listing, Indivior will remain under the jurisdiction of the UK Takeover Code for a defined transition period. This ensures that existing corporate governance and acquisition safeguards remain active during the period following the delisting. The company will continue to operate under the oversight provisions relevant to its UK incorporation.
Market Alignment and Regulatory Oversight Maintained
The company’s realignment reflects a broader corporate strategy that mirrors its operational concentration in the U.S. While the exit from the London market marks a structural adjustment, the ongoing compliance with UK governance regulations and sustained presence on Nasdaq demonstrate Indivior’s intent to maintain both regulatory discipline and global market access.
